AVALO THERAPEUTICS, INC. (AVTX)

Every figure this model derived for AVTX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquireOtherPropertyPlantAndEquipment 2023-12-31
cash 400,276,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 407,932,000 AssetsCurrent 2026-06-30
current liabilities 21,130,000 LiabilitiesCurrent 2026-06-30
equity 448,660,000 StockholdersEquity 2026-06-30
interest expense 0 InterestPaidNet 2024-12-31
ocf -68,290,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 59,000 RevenueFromContractWithCustomerExcludingAssessedTax 2025-12-31
sbc 16,542,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up AVTX on one particular measure came for.

RatioValue
current ratio19.31
current ratio reported19.31
deferred revenue growth-100.0
dilution pct78.89
revenue growth-86.62
revenue growth per share-92.52
roic-149.17
rule of 40-154930.69

What to be careful about

What this model itself distrusts about AVTX's figures. Written by the derivation as it ran, not added afterwards.